Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 7/20 | 0.56 |
| ▸ | CASP3 | P42574 | 3/20 | 0.49 |
| ▸ | TLR2 | O60603 | 2/20 | 0.46 |
| ▸ | CTSB | P07858 | 1/20 | 0.46 |
| ▸ | CTSK | P43235 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.44 |
| ▸ | GRB2 | P62993 | 1/20 | 0.44 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29431036 | 0.95 | CASP3 (0.53) | PTPN1CASP3TLR2KMT2AMDM2 | |
| SCHEMBL30163210 | 0.91 | PTPN1 (0.53) | PTPN1CASP3TLR2CTSBCTSK | |
| SCHEMBL30386840 | 0.91 | PTPN1 (0.64) | PTPN1CASP3TLR2KMT2AMDM2 | |
| SCHEMBL29462949 | 0.91 | PTPN1 (0.64) | PTPN1CASP3TLR2KMT2AMDM2 | |
| SCHEMBL31564904 | 0.88 | PTPN1 (0.56) | PTPN1CASP3TLR2CTSBCTSK | |
| SCHEMBL29462951 | 0.88 | CASP3 (0.49) | PTPN1CASP3TLR2MDM2 | |
| SCHEMBL28359771 | 0.86 | CASP3 (0.62) | PTPN1CASP3TLR2KMT2AMDM2 | |
| SCHEMBL28359770 | 0.86 | CASP3 (0.62) | PTPN1CASP3TLR2KMT2AMDM2 | |
| SCHEMBL30968394 | 0.86 | TLR2 (0.48) | PTPN1CASP3TLR2KMT2AMDM2 | |
| SCHEMBL30945915 | 0.86 | CTSB (0.51) | PTPN1CASP3CTSBCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240319146-A1 | ANALYSIS METHOD FOR PEPTIDE BOUND TO CARRIER FOR LIQUID PHASE PEPTIDE SYNTHESIS | PEPTISTAR INC. (JP) | 2024-09-26 | — | — | US | disclosed |
| EP-4365184-A1 | ANALYSIS METHOD FOR PEPTIDE BOUND TO CARRIER FOR LIQUID PHASE PEPTIDE SYNTHESIS | Peptistar Inc. (JP) | 2024-05-08 | — | — | EP | disclosed |
| WO-2023277186-A1 | ANALYSIS METHOD FOR PEPTIDE BOUND TO CARRIER FOR LIQUID PHASE PEPTIDE SYNTHESIS | ペプチスター株式会社 | 2023-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240319146-A1 | ANALYSIS METHOD FOR PEPTIDE BOUND TO CARRIER FOR LIQUID PHASE PEPTIDE SYNTHESIS | HDGF, VIP, NPPA | PTPN1 4090/4885CASP3 4685/4885TLR2 4291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.